PMID- 34915579
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20221025
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 32
IP  - 6
DP  - 2022 Oct 15
TI  - Efficacy and safety of high-dose of mycophenolate mofetil compared with 
      cyclophosphamide pulse therapy as induction therapy in Japanese patients with 
      proliferative lupus nephritis.
PG  - 1077-1085
LID - 10.1093/mr/roab113 [doi]
AB  - OBJECTIVES: To clarify the effectiveness and safety of induction therapy with 
      mycophenolate mofetil (MMF) in patients with lupus nephritis (LN). METHODS: 
      Patients with LN administered MMF (n = 35) or intravenous cyclophosphamide pulse 
      therapy (IVCY) (n = 25) plus high-dose corticosteroids between July 2015 and June 
      2020 were included. MMF was increased from 2 to 3 g/day, with no adverse events 
      (AEs). The primary endpoint was the 6 month renal remission rate. Secondary 
      endpoints were retention rate and AEs. RESULTS: There were no significant 
      differences in age, sex, disease duration, renal histological type, SLE disease 
      activity index, and urine protein creatinine ratio between the two groups. 
      Twenty-six patients (74%) continued with MMF therapy, whereas 12 (48%) completed 
      six IVCY courses. The retention rate was significantly higher in the MMF than in 
      the IVCY group (p = 0.048). Twenty-four and 14 patients in MMF and IVCY groups, 
      respectively, achieved renal remission with insignificant differences. Grade 3 or 
      higher AEs were observed in 8 and 14 patients in the MMF and IVCY groups, 
      respectively (p = 0.014). CONCLUSIONS: The efficacy of high-dose MMF was 
      comparable to that of IVCY in Japanese patients with proliferative LN, with fewer 
      AEs and a higher retention rate than IVCY, suggesting the high tolerability of 
      MMF.
CI  - (c) Japan College of Rheumatology 2021. Published by Oxford University Press. All 
      rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Ohkubo, Naoaki
AU  - Ohkubo N
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Iwata, Shigeru
AU  - Iwata S
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Nakano, Kazuhisa
AU  - Nakano K
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Miyagawa, Ippei
AU  - Miyagawa I
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Hanami, Kentaro
AU  - Hanami K
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Fukuyo, Shunsuke
AU  - Fukuyo S
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Miyazaki, Yusuke
AU  - Miyazaki Y
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Kawabe, Akio
AU  - Kawabe A
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Nakayamada, Shingo
AU  - Nakayamada S
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
FAU - Tanaka, Yoshiya
AU  - Tanaka Y
AD  - The First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Kitakyushu, Japan.
LA  - eng
GR  - 19K17919/the University of Occupational and Environmental Health/
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - AYI8EX34EU (Creatinine)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 0 (Immunosuppressive Agents)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Humans
MH  - Creatinine/therapeutic use
MH  - Cyclophosphamide/adverse effects
MH  - Immunosuppressive Agents/adverse effects
MH  - Induction Chemotherapy
MH  - Japan
MH  - *Lupus Nephritis/drug therapy
MH  - *Mycophenolic Acid/adverse effects
MH  - Remission Induction
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Induction therapy
OT  - lupus nephritis
OT  - mycophenolate mofetil
OT  - systemic lupus erythematosus
EDAT- 2021/12/17 06:00
MHDA- 2022/10/19 06:00
CRDT- 2021/12/16 20:40
PHST- 2021/08/17 00:00 [received]
PHST- 2021/10/19 00:00 [revised]
PHST- 2021/11/16 00:00 [accepted]
PHST- 2021/12/17 06:00 [pubmed]
PHST- 2022/10/19 06:00 [medline]
PHST- 2021/12/16 20:40 [entrez]
AID - 6463547 [pii]
AID - 10.1093/mr/roab113 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2022 Oct 15;32(6):1077-1085. doi: 10.1093/mr/roab113.